Retrospective analysis reveals chronic hepatitis B patients with criteria show minimal risk of HCC and may not need antiviral therapy.
Key Points
True immune tolerant hepatitis B patients exhibit minimal risk of severe liver events, significantly lower 10-year HCC rates than other groups.
Among 1064 chronic hepatitis B patients, those meeting strict criteria had no HCC cases and lower progression likelihood to immune-active status.
Analysis of clinical outcomes from a retrospective cohort corroborated key demographic factors such as younger age and female gender in lower risk profiles.
This research underscores the need for precise classification of immune tolerant patients to avoid unnecessary antiviral therapy.